Profile data is unavailable for this security.
About the company
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
- Revenue in AUD (TTM)62.85m
- Net income in AUD8.34m
- Incorporated1999
- Employees61.00
- LocationCogState LtdLevel 2, 161 Collins StreetMELBOURNE 3000AustraliaAUS
- Phone+61 39664-1300
- Fax+61 39664-1301
- Websitehttps://cogstate.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recce Pharmaceuticals Ltd | 6.81m | -11.32m | 122.39m | -- | -- | 228.80 | -- | 17.96 | -0.0637 | -0.0637 | 0.0385 | 0.0026 | 1.68 | -- | 52.84 | -- | -279.04 | -110.82 | -985.91 | -139.61 | -- | -- | -166.11 | -391.79 | -- | -24.07 | 0.2712 | -- | 39.53 | 27.79 | -19.03 | -- | -26.31 | -- |
| Arovella Therapeutics Ltd | 139.02k | -10.23m | 126.02m | 14.00 | -- | 34.84 | -- | 906.48 | -0.0127 | -0.0127 | 0.0002 | 0.0034 | 0.0249 | -- | 15.15 | -- | -182.82 | -77.12 | -276.07 | -93.26 | 83.56 | 63.41 | -7,357.19 | -1,471.57 | -- | -- | 0.00 | -- | 45.47 | 0.3491 | -18.11 | -- | -68.72 | -- |
| Vita Life Sciences Limited | 74.16m | 9.08m | 131.00m | 124.00 | 14.15 | 3.05 | 13.66 | 1.77 | 0.166 | 0.166 | 1.36 | 0.7695 | 1.33 | 2.34 | 7.35 | -- | 16.27 | 15.25 | 22.51 | 21.99 | 58.14 | 60.90 | 12.24 | 11.71 | 2.29 | -- | 0.0089 | 39.05 | 10.88 | 12.50 | 28.18 | 30.07 | 12.15 | 19.14 |
| Proteomics International LaboratoriesLtd | 1.44m | -5.90m | 133.51m | -- | -- | 23.32 | -- | 92.40 | -0.0518 | -0.0518 | 0.0129 | 0.0437 | 0.1817 | -- | 11.13 | -- | -75.75 | -57.79 | -87.11 | -67.57 | -- | -- | -416.78 | -229.69 | -- | -283.47 | 0.0088 | -- | -14.64 | 4.12 | -24.20 | -- | 89.02 | -- |
| Dimerix Ltd | 181.28k | -10.87m | 186.89m | 0.00 | -- | 84.39 | -- | 1,030.94 | -0.0294 | -0.0294 | 0.0005 | 0.004 | 0.0169 | -- | 0.7586 | -- | -101.36 | -70.77 | -128.88 | -110.81 | -- | -- | -5,994.52 | -61,882.73 | -- | -- | 0.4541 | -- | 1,452.32 | 12.76 | -31.57 | -- | -8.26 | -- |
| Cogstate Ltd | 62.85m | 8.34m | 212.56m | 61.00 | 27.76 | 3.70 | 16.99 | 3.38 | 0.0447 | 0.0447 | 0.3406 | 0.3352 | 0.7757 | -- | 5.58 | -- | 10.30 | 6.01 | 13.84 | 9.22 | 54.69 | 51.50 | 13.28 | 7.26 | -- | -- | 0.0135 | 0.00 | -8.62 | 7.25 | -52.56 | -- | -5.06 | -- |
| Probiotec Ltd | 221.22m | 8.69m | 239.09m | 111.00 | 28.32 | 2.71 | 9.99 | 1.08 | 0.1038 | 0.1038 | 2.64 | 1.09 | 0.9483 | 7.03 | 6.99 | -- | 3.72 | 4.58 | 5.36 | 5.94 | 29.95 | 30.21 | 3.93 | 5.73 | 1.09 | 3.33 | 0.4937 | 47.90 | 17.39 | 23.10 | -19.61 | 20.84 | 12.97 | 18.77 |
| Race Oncology Ltd | 885.59k | -11.17m | 242.50m | -- | -- | 11.60 | -- | 273.83 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Australian Ethical Investments Ltd. (Investment Management)as of 30 Jun 2023 | 14.38m | 8.39% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Mar 2024 | 4.95m | 2.89% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 31 Mar 2024 | 1.95m | 1.14% |
| Mutual Trust Pty Ltd.as of 30 Jun 2023 | 1.22m | 0.71% |
| DFA Australia Ltd.as of 30 Apr 2024 | 725.69k | 0.42% |
| Seven Canyons Advisors LLCas of 31 Dec 2023 | 686.01k | 0.40% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 466.43k | 0.27% |
| Mandarine Gestion SAas of 29 Feb 2024 | 45.00k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 09 May 2024 | 13.68k | 0.01% |
| Adirondack Retirement Specialists, Inc.as of 30 Sep 2023 | 0.00 | 0.00% |
